Renal Clearable Luminescent Gold Nanoparticles: From the Bench to the Clinic.

ABSTRACT: With more and more engineered nanoparticles (NPs) being translated to the clinic, the United States Food and Drug Administration (FDA) has recently issued the latest draft guidance on nanomaterial-containing drug products with an emphasis on understanding their in vivo transport and nano-bio interactions. Following these guidelines, NPs can be designed to target and treat diseases more efficiently than small molecules, have minimum accumulation in normal tissues, and induce minimum toxicity. In this Minireview, we integrate this guidance with our ten-year studies on developing renal clearable luminescent gold NPs. These gold NPs resist serum protein adsorption, escape liver uptake, target cancerous tissues, and report kidney dysfunction at early stages. At the same time, off-target gold NP

SUBMITTER: Yu M 

PROVIDER: S-EPMC6943938 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature